Maureen J Lage

List of Publications by Year
in descending order

48 papers	1,365 citations	361413 20 h-index	345221 36 g-index
49 all docs	49 docs citations	49 times ranked	1746 citing authors

#	Article	IF	Citations
1	The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis. Diabetes Therapy, 2022, 13, 367-377.	2.5	5
2	The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. Advances in Therapy, 2022, 39, 2208-2221.	2.9	13
3	The Association Between Switching from SynthroidÂ® and Clinical Outcomes: US Evidence from a Retrospective Database Analysis. Advances in Therapy, 2021, 38, 337-349.	2.9	2
4	Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study. Diabetes Therapy, 2021, 12, 1463-1474.	2.5	1
5	Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012â€“2019. Diabetes Therapy, 2021, 12, 2077-2087.	2.5	19
6	Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018. Journal of Diabetes Science and Technology, 2021, , 193229682110282.	2.2	7
7	Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data. Journal of Diabetes and Its Complications, 2021, 35, 107975.	2.3	17
8	The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database. Current Medical Research and Opinion, 2020, 36, 1441-1447.	1.9	34
9	Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. Journal of Diabetes and Its Complications, 2020, 34, 107730.	2.3	9
10	The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1081-1089.	0.9	6
11	The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes. Clinical Therapeutics, 2020, 42, 1812-1817.e2.	2.5	3
12	Chronic Medication Burden and Complexity for US Patients with TypeÂ2 Diabetes Treated with Glucose-Lowering Agents. Diabetes Therapy, 2020, 11, 1513-1525.	2.5	7
13	Generalizability of glucagonâ€like peptideâ€1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes, Obesity and Metabolism, 2019, 21, 1299-1304.	4.4	36
14	The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes. Journal of Medical Economics, 2019, 22, 447-454.	2.1	9
15	Comment on generalizability of GLP-1 RA CVOTs in US T2D population. American Journal of Managed Care, 2019, 25, 170-171.	1.1	2
16	Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population. Diabetes Therapy, 2018, 9, 637-650.	2.5	19
17	Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes. Diabetes Therapy, 2018, 9, 1099-1111.	2.5	21
18	The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US. Journal of Medical Economics, 2018, 21, 912-919.	2.1	24

#	Article	IF	Citations
19	Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting. Clinical Therapeutics, 2018, 40, 1396-1407.	2.5	5
20	Medication adherence and improved outcomes among patients with type 2 diabetes. American Journal of Managed Care, 2017, 23, e208-e214.	1.1	25
21	Insulin Dosing and Outcomes Among Commercially Insured Patients With Type 2 Diabetes in the United States. Clinical Therapeutics, 2015, 37, 2297-2308.e1.	2.5	7
22	Outcomes of Medicaid Beneficiaries With Schizophrenia Receiving Clozapine Only or Antipsychotic Combinations. Psychiatric Services, 2015, 66, 127-133.	2.0	30
23	Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. Journal of Medical Economics, 2014, 17, 21-31.	2.1	23
24	Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Services Research, 2014, 14, 286.	2.2	32
25	Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus. Diabetes Therapy, 2014, 5, 225-242.	2.5	45
26	Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2013, 29, 1587-1597.	1.9	1
27	The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study. Journal of Medical Economics, 2013, 16, 1231-1237.	2.1	13
28	Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer. Journal of Medical Economics, 2010, 13, 691-697.	2.1	8
29	Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. Journal of Medical Economics, 2010, 13, 464-471.	2.1	14
30	Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Advances in Therapy, 2009, 26, 217-229.	2.9	12
31	Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Advances in Therapy, 2009, 26, 552-562.	2.9	20
32	Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate. Advances in Therapy, 2009, 26, 762-775.	2.9	6
33	The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Annals of General Psychiatry, 2009, 8, 7.	2.7	56
34	A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Applied Health Economics and Health Policy, 2009, 7, 245-254.	2.1	16
35	Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients. Advances in Therapy, 2008, 25, 658-673.	2.9	11
36	Obesity and the use of insulin: a study of patients with type 2 diabetes in the UK. Journal of Diabetes and Its Complications, 2008, 22, 235-240.	2.3	5

#	Article	IF	Citations
37	Costs and Resource Use of Mild Persistent Asthma Patients Initiated on Controller Therapy. Journal of Asthma, 2008, 45, 293-299.	1.7	25
38	The cost of treating skeletal-related events in patients with prostate cancer. American Journal of Managed Care, 2008, 14, 317-22.	1.1	100
39	Patterns of blood glucose monitoring in relation to glycemic control among patients with type 2 diabetes in the UK. Journal of Diabetes and Its Complications, 2007, 21, 181-186.	2.3	10
40	Trends in the prescription of antidiabetic medications in France: Evidence from primary care physicians. Advances in Therapy, 2007, 24, 803-813.	2.9	28
41	Medication Use, Service Utilization, and Medical Costs Associated With New Episodes of Bipolar Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 280-286.	0.6	8
42	The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Effectiveness and Resource Allocation, 2006, 4, 1.	1.5	96
43	Effect of methylphenidate formulation on treatment patterns and use of emergency room services. American Journal of Health-System Pharmacy, 2006, 63, 317-322.	1.0	21
44	The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depression and Anxiety, 2005, 21, 178-184.	4.1	157
45	Comorbidities and Costs of Adult Patients Diagnosed with Attention-Deficit Hyperactivity Disorder. Pharmacoeconomics, 2005, 23, 93-102.	3.3	189
46	Medical and productivity costs of anxiety disorders: Case control study. Depression and Anxiety, 2004, 19, 112-120.	4.1	80
47	Effect of Methylphenidate Formulation for Attention Deficit Hyperactivity Disorder on Patterns and Outcomes of Treatment. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 575-581.	1.3	45
48	Olanzapine versus Risperidone in the Treatment of Schizophrenia. Pharmacoeconomics, 2003, 21, 683-697.	3.3	43